Zyprexa Zydis

Delirium, Delusional Parasitosis, Schizophrenia + 11 more
Treatment
8 FDA approvals
20 Active Studies for Zyprexa Zydis

What is Zyprexa Zydis

OlanzapineThe Generic name of this drug
Treatment SummaryOlanzapine is an atypical antipsychotic medication used to treat mental health conditions. It was introduced in the 1990s and is known for its effectiveness, reduced risk of side effects and low chance of drug-drug interactions. Olanzapine is similar to clozapine but has two additional methyl groups and no chloride moiety. It was approved by the FDA and released in the US in 1996.
Zyprexais the brand name
image of different drug pills on a surface
Zyprexa Zydis Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Zyprexa
Olanzapine
1996
546

Approved as Treatment by the FDA

Olanzapine, otherwise known as Zyprexa, is approved by the FDA for 8 uses which include Mental Depression and Bipolar Disorder .
Mental Depression
Used to treat Acute Depressive Episode in combination with Fluoxetine
Bipolar Disorder
Used to treat Bipolar 1 Disorder in combination with Fluoxetine
Bipolar Disorder
Used to treat Bipolar Disorder With Manic or Mixed Episodes in combination with Lithium cation
Unipolar Depression
Used to treat Major depressive disorder, recurrent episode in combination with Fluoxetine
Bipolar Disorder With Manic or Mixed Episodes
Used to treat Bipolar Disorder With Manic or Mixed Episodes in combination with Lithium cation
Bipolar 1 Disorder
Used to treat Bipolar 1 Disorder in combination with Fluoxetine
Acute Depressive Episode
Used to treat Acute Depressive Episode in combination with Fluoxetine
Major depressive disorder, recurrent episode
Used to treat Major depressive disorder, recurrent episode in combination with Fluoxetine

Effectiveness

How Zyprexa Zydis Affects PatientsOlanzapine works by targeting the dopamine D2 receptor and the serotonin 5HT2A receptor in the body. This helps to decrease hallucinations, delusions, disorganized speech, disorganized thought, and disorganized behavior, as well as improve feelings of sadness, lack of energy, lack of interest in activities, difficulty making decisions, and poor attention. Olanzapine has been shown to be effective in treating schizophrenia and bipolar disorder in adults and reducing manic or mixed episodes in adolescents. It has also been studied for its ability to reduce nausea and vomiting caused by chemotherapy, with studies showing that it can help control these symptoms in over 80
How Zyprexa Zydis works in the bodyOlanzapine works by blocking receptors in the brain, including receptors for dopamine and serotonin. This blocking prevents dopamine from having an effect on the post-synaptic receptor. Olanzapine also blocks serotonin receptors in the frontal cortex, which helps reduce side effects.

When to interrupt dosage

The advised dosage of Zyprexa Zydis is contingent upon the recognized condition, such as Schizophrenia, Bipolar Disorder and Delirium. The measure of dosage fluctuates as per the method of administration (e.g. Kit - Intramuscular or Tablet, film coated - Oral) detailed in the table beneath.
Condition
Dosage
Administration
Delirium
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit
Schizophrenia
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit
Schizophrenia
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit
Bipolar Disorder
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit
Post Traumatic Stress Disorder
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit
Tourette Syndrome
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit
Mental Depression
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit
Acute Agitation
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit
Unipolar Depression
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit
Acute Coryza
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit
Delusional Parasitosis
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit
Bipolar Disorder
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit
Alzheimer's Disease
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit
Bipolar Disorder
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit

Warnings

There are 20 known major drug interactions with Zyprexa Zydis.
Common Zyprexa Zydis Drug Interactions
Drug Name
Risk Level
Description
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Olanzapine.
Acepromazine
Major
Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.
Aclidinium
Major
The risk or severity of adverse effects can be increased when Olanzapine is combined with Aclidinium.
Alfuzosin
Major
Olanzapine may increase the hypotensive activities of Alfuzosin.
Amisulpride
Major
Olanzapine may increase the antipsychotic activities of Amisulpride.
Zyprexa Zydis Toxicity & Overdose RiskTaking too much olanzapine can cause drowsiness, enlarged pupils, slow or shallow breathing, low blood pressure, muscle stiffness, dry mouth, and confusion. In more severe cases, people may experience agitation, slurred speech, fast heartbeat, and reduced consciousness. In rare cases, taking too much olanzapine can even lead to death. If someone has overdosed on olanzapine, it is important to ensure they are getting enough oxygen and to give them activated charcoal with a laxative. Animal studies have linked olanzapine to an increased risk of liver tumors, mammary gland tumors
image of a doctor in a lab doing drug, clinical research

Zyprexa Zydis Novel Uses: Which Conditions Have a Clinical Trial Featuring Zyprexa Zydis?

At present, 578 active clinical trials are evaluating the potential of Zyprexa Zydis to alleviate Schizophrenia, Post Traumatic Stress Disorder and Delusional Parasitosis.
Condition
Clinical Trials
Trial Phases
Schizophrenia
97 Actively Recruiting
Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2
Post Traumatic Stress Disorder
239 Actively Recruiting
Not Applicable, Early Phase 1, Phase 3, Phase 4, Phase 2, Phase 1
Bipolar Disorder
0 Actively Recruiting
Schizophrenia
32 Actively Recruiting
Early Phase 1, Not Applicable, Phase 4
Mental Depression
2 Actively Recruiting
Phase 2, Not Applicable
Delirium
26 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 4, Early Phase 1
Unipolar Depression
48 Actively Recruiting
Not Applicable, Phase 4, Early Phase 1, Phase 3, Phase 2, Phase 1
Bipolar Disorder
0 Actively Recruiting
Bipolar Disorder
0 Actively Recruiting
Delusional Parasitosis
0 Actively Recruiting
Alzheimer's Disease
39 Actively Recruiting
Phase 4, Phase 2, Phase 3, Not Applicable, Phase 1
Acute Coryza
1 Actively Recruiting
Not Applicable
Acute Agitation
0 Actively Recruiting
Tourette Syndrome
0 Actively Recruiting

Zyprexa Zydis Reviews: What are patients saying about Zyprexa Zydis?

5Patient Review
2/18/2012
Zyprexa Zydis for Additional Medications to Treat Depression
Zydis has really helped me. I've experienced an increase in appetite and weight gain, but it's worth it for the relief it provides.
5Patient Review
7/19/2009
Zyprexa Zydis for Additional Medications to Treat Depression
I found this medication to be really great. I had no issues with weight gain, depression, anxiety, or concentration at a dose of 10 mg at night.
5Patient Review
1/10/2009
Zyprexa Zydis for Mental Disorder with Loss of Normal Personality & Reality
I am so pleased with this medication. I only wish I had started taking it sooner.
5Patient Review
12/2/2008
Zyprexa Zydis for Bipolar Disorder in Remission
If you've gained weight, get active and go to the gym or something! Zyprexa has always worked for me and I haven't had any issues for years now.
3.7Patient Review
10/2/2009
Zyprexa Zydis for Mental Disorder with Loss of Normal Personality & Reality
I am a 240 pound, 5'5" male with high cholesterol and triglycerides.
3.3Patient Review
4/13/2009
Zyprexa Zydis for Schizophrenia
Worked great at first, but then the effects petered out after a few months. I still experienced some side effects even after it stopped being effective which were mostly increased appetite and fatigue. Your experience may be different, but mine was not good.
3Patient Review
11/6/2007
Zyprexa Zydis for Bipolar I Disorder with Most Recent Episode Mixed
I find that if I don't take this medication, I feel more anxious; however, it doesn't seem to do much else. The downside is that I've experienced severe weight gain as a result of taking it.
3Patient Review
4/23/2012
Zyprexa Zydis for Bipolar I Disorder with Most Recent Episode Mixed
This medication was successful in curbing her manic episodes of anxiety and anger. However, once it hit her system she became incredibly depressed and would cry for hours on end. We haven't decided if we will continue using it yet.
3Patient Review
8/25/2011
Zyprexa Zydis for Schizophrenia
My weight has been more unstable since I began taking this medication.
2.7Patient Review
12/28/2007
Zyprexa Zydis for Additional Medications to Treat Depression
I've found that my symptoms have actually gotten worse since starting this medication, and I've also gained weight.
1Patient Review
11/10/2009
Zyprexa Zydis for Manic-Depression
I haven't tried it yet.
1Patient Review
5/25/2014
Zyprexa Zydis for Bipolar I Disorder with Most Recent Episode Mixed
I gained a ton of weight in just three weeks from using this. Please, look for something else!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zyprexa zydis

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Zyprexa and Zyprexa Zydis the same thing?

"Zyprexa Zydis wafers are just as effective as Zyprexa coated tablets, with a similar rate and extent of absorption. Zyprexa Zydis wafers have the same dosage and frequency of administration as Zyprexa coated tablets. Zyprexa Zydis wafers may be used as an alternative to Zyprexa coated tablets."

Answered by AI

How long does it take for Zyprexa Zydis to dissolve?

"For treating bipolar disorder on a long-term basis, the recommended dose of olanzapine is 5-20 mg per day. The orally disintegrating tablet form of olanzapine is placed in your mouth, where it will dissolve within a few seconds."

Answered by AI

How do you administer Zyprexa Zydis?

"To take ZYPREXA ZYDIS (olanzapine orally disintegrating tablets), open the sachet and peel back the foil on the blister. Do not push the tablet through the foil. Using dry hands, remove the tablet from the blister and place the entire tablet in your mouth."

Answered by AI

What is Zyprexa Zydis used for?

"Olanzapine belongs to a class of drugs called atypical antipsychotics.

Olanzapine is a drug used to treat mental and mood conditions such as schizophrenia and bipolar disorder. It may also be used to treat depression in combination with other medications. Olanzapine belongs to a class of drugs called atypical antipsychotics."

Answered by AI

Clinical Trials for Zyprexa Zydis

Image of University of Rochester Medical Center in Rochester, United States.

Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression

18+
All Sexes
Rochester, NY
The goal of this clinical trial is to understand the effect of ketamine on the brain in people with treatment-resistant depression (TRD). TRD occurs in around a third of people with depression and leads to higher suicide rates compared to those with major depressive disorder. A desperate need for a rapid acting antidepressant drug (RAAD) is needed to help improve quality of life for people with TRD. Ketamine has been shown to be a RAAD, and esketamine (a form of ketamine) was approved by the FDA to treat TRD. Ketamine has been known to cause dissociative experiences, that can lead to an increase in the "Openness to Experience" personality trait and psychological flexibility that occurs at "peak experience". This has been shown to improve mental health conditions and lower suicide risk. Our study aims to further understand if there is a connection between this new change of mind and changes in brain activity. Ketamine has been shown to improve brain plasticity as well, specifically in the frontolimbic region of the brain, an area associated with depression. We are analyzing the brain using functional magnetic resonance imaging (fMRI), a method used to measure brain activity. The frontolimbic region is also associated with cognitive flexibility and emotional processing, an important hurdle in treating TRD. Due to this, we are pairing the ketamine treatment with psychotherapy sessions, to guide the processing experience, which can lead to higher emotional flexibility. The main questions this study aims to answer are: * Are frontolimibic plasticity circuitry changes associated with openness to experience and peak experience? * Is it feasible to recruit and retain people through a two-month study? * Is the structure of the study effective for treating TRD? Participants will: * Visit the facilities 6-8 times * Complete 2 MRI brain scans * Complete 3-4 psychotherapy sessions * Receive 1-2 doses of ketamine * Complete online surveys between 3-4 visits
Phase 2
Waitlist Available
University of Rochester Medical Center
Image of Duke University School of Medicine in Durham, United States.

Cognitive Rehabilitation for Anger in TBI and PTSD

18+
All Sexes
Durham, NC
This randomized clinical trial will enroll 100 Veteran-family/friend dyads to test the efficacy of CALM in treating anger in TBI and PTSD. The investigators hypothesize that compared to an active control group, Veterans randomized to the CALM group will demonstrate: * Significantly larger decreases in anger dysregulation, impulsivity, and executive dysfunction. * Significantly larger improvements in social and adaptive functioning including less aggression. * Significantly larger reduction in PTSD symptoms and suicidal ideation. The study targets Veterans who experience difficulties with anger and impulsivity due to TBI and PTSD. These issues are common, with up to 38% of Veterans with TBI also having PTSD. These conditions often make it challenging for Veterans to control their emotions and interact successfully in social and work settings. Our research will test the CALM (Cognitive Applications for Life Management) mobile app, which helps Veterans manage their goals, remember important tasks, and improve their attention. Initial tests of CALM have shown it can reduce levels of anger and related issues in Veterans. The investigators will conduct a study with 100 pairings of Veterans and a family member or friend. These pairs will be randomly assigned to one of two groups: one using the CALM mobile platform and the other receiving brain health education. Both groups will use their assigned intervention for three months and will receive support through videoconference calls at the beginning, middle, and end of the program.
Waitlist Available
Has No Placebo
Duke University School of MedicineEric Elbogen
Image of Cohen and Associates in Sarasota, United States.

NRX-101 + TMS for Treatment Resistant Depression

18 - 80
All Sexes
Sarasota, FL
Major depressive disorder (MDD) is a significant public health problem and leading cause of worldwide disability. Treatment resistance is common in MDD, however, for these individuals, targeted noninvasive brain stimulation is an alternative. Repetitive transcranial magnetic stimulation (rTMS) and more recently, theta-burst stimulation (TBS), are the noninvasive brain stimulation modalities with the largest evidence base in MDD. Although efficacious, an unacceptable proportion of patients do not significantly improve, and several aspects of the TMS parameter space are under investigation to enhance clinical outcomes. DCS has been shown in a randomized trial of more than double the percent response and remission from traditional TMS. When the AMPA one day (ONE-D) TMS protocol was combined with DCS, the measured response rate was 87% at one week. This trial will compare response and remission at six weeks following Transcranial Magnetic Stimulation + D-cycloserine vs. TMS+placebo.
Phase 2 & 3
Waitlist Available
Cohen and AssociatesNeuroRx, Inc.
Have you considered Zyprexa Zydis clinical trials? We made a collection of clinical trials featuring Zyprexa Zydis, we think they might fit your search criteria.Go to Trials
Image of Scottsdale Research Institute in Cave Creek, United States.

Inhaled Cannabis for PTSD

18+
All Sexes
Cave Creek, AZ
The rationale for the use of inhalational cannabis to potentially treat PTSD symptoms is based on the many reports of cannabis attenuating PTSD symptom expression among individuals with PTSD, including veterans. Study MJP2 is intended to build off MJP-1 through use of a larger sample size, a parallel study design, and subjective bias mitigation methods to re-examine the use of inhaled high THC-containing cannabis versus placebo for management of PTSD symptoms in a U.S. Veteran sample. Together these studies are intended to provide valuable insights on the already widespread use of cannabis in individuals with PTSD, for which there is currently a lack of controlled evidence available reflective of this real-world use.
Phase 2
Waitlist Available
Scottsdale Research Institute
Image of CSMC in Los Angeles, United States.

Photobiomodulation for Alzheimer's Disease

55 - 89
All Sexes
Los Angeles, CA
The purpose of this study is to see if a special light treatment, called photobiomodulation, can help people with memory problems such as Mild Cognitive Impairment or Mild Dementia due to Alzheimer's disease. The light is given to the forehead using an FDA-cleared medical device. This device is cleared to provide topical heating to elevate tissue temperature for temporary relief of muscle and joint pain, muscle spasm and stiffness associated with arthritis. It also increases blood circulation and relaxes muscle tissue. This device is being used "off-label," meaning it will be used in a way that is different than its cleared use. We want to learn whether this light treatment can improve executive function, and whether it changes certain inflammatory and neurodegeneration related signals in the blood. To do this, we will apply the photobiomodulation device to your forehead. We will also ask you questions and give you cognitive tests before and after light treatment. We will also collect blood samples before and after treatment.
Recruiting
New This Month
CSMCGolnaz Yadollahikhales, MD
Image of VA Phoenix Healthcare System in Phoenix, United States.

Integrated Health Care for Post-Traumatic Stress Disorder

18+
All Sexes
Phoenix, AZ
The goal of this clinical trial is to determine whether which types of integrative care, meaning a combination of psychotherapy and mind-body interventions, lead to the most changes in functioning among Veterans with posttraumatic stress disorder (PTSD). The main aims are: 1. To evaluate the impact of integrative care approaches on functional outcomes among Veterans with PTSD. 2. To examine factors relevant to the implementation of integrated treatments for PTSD from the perspective of patients, providers and administrators in the VA Healthcare System. Participants will: 1. Complete assessments at the beginning of the study and 12- and 24-weeks later. 2. Engage in 12 weeks of integrated care, with the type being randomly assigned.
Waitlist Available
Has No Placebo
VA Phoenix Healthcare System (+4 Sites)
Have you considered Zyprexa Zydis clinical trials? We made a collection of clinical trials featuring Zyprexa Zydis, we think they might fit your search criteria.Go to Trials
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA
The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.
Waitlist Available
Has No Placebo
The University of Iowa
Image of UCSD Interventional Psychiatry in San Diego, United States.

Transcranial Direct Current Stimulation for Depression

18 - 85
All Sexes
San Diego, CA
The investigators propose a single-arm, open-label study to evaluate the effectiveness, safety, tolerability and feasibility of at-home transcranial direct current stimulation (tDCS) as a treatment for depression, particularly in cases where patients have not responded well to traditional therapies. Treatment will be delivered over a 2-week period with daily weekday treatments i.e., five tDCS sessions, each lasting 20 minutes, spaced by approximately 20-minute inter-session intervals, for a total of three hours a day. Participants will self-administer treatment at home under direct remote supervision. Pre- and post- treatment neurophysiological biomarkers sessions will also be carried out. The study aims to examine changes in mood, brain activity, and related clinical outcomes before, during, and after treatment, with the goal to provide more information that can be used for future studies.
Recruiting
Has No Placebo
UCSD Interventional Psychiatry
Image of UCLA Semel Institute for Neuroscience and Human Behavior in Los Angeles, United States.

Deep Brain Stimulation for Anxiety Disorders

18 - 70
All Sexes
Los Angeles, CA
The goal of this clinical trial is to learn how people respond to fear-related experiences in a virtual reality (VR) environment. The study will also look at how brain activity and body responses are connected to learning and memory of fear. To do so, we recruit individuals who are already implanted with a Responsive Neurostimulator (RNS) device for the treatment of epilepsy. This research may help improve our understanding of anxiety disorders and how to better treat them in the future. The main questions it aims to answer are: 1) How do people learn to associate certain cues in VR with feelings of fear or safety? 2) What brain and body responses happen during fear learning? Participants will: 1) Wear a virtual reality headset and experience different environments and sounds, 2) Have their brain activity, heart rate, and sweating measured, and 3) Receive safe, mild electrical pulses through the RNS device during the study to help study fear learning. Participants will attend one or more study sessions, each lasting about 3-4 hours.
Waitlist Available
Has No Placebo
UCLA Semel Institute for Neuroscience and Human Behavior
Have you considered Zyprexa Zydis clinical trials? We made a collection of clinical trials featuring Zyprexa Zydis, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security